Bio-Gene Technology Limited (ASX:BGT) Announces Positive Flavocide Efficacy Results
Flavocide Efficacy Results
Bio-Gene Technology Limited (ASX:BGT) announced that Flavocide®, formulated in a prototype emulsion, achieved over 90% mortality of Ixodes scapularis nymphs within 24 hours. The results also demonstrated residual activity for up to four weeks under controlled laboratory conditions, validating Flavocide’s acaricidal potential.
Conference Presentation
The efficacy results were presented by researchers from Purdue University at the 17th International Conference on Lyme Borreliosis and Other Tick-Borne Diseases in Chicago, USA. The announcement was made publicly on the ASX Market Announcements Platform on 23 September 2025.
Market Impact
Following the announcement, BGT’s securities saw a significant increase of 87%, rising from a closing price of $0.033 on 22 September 2025 to a high of $0.058.
ASX Compliance
Bio-Gene Technology Limited confirmed its compliance with ASX Listing Rules, including immediate disclosure of market-sensitive information. The company ensured that all responses to ASX queries were authorised and approved in accordance with its continuous disclosure policy.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
